While T-BsAb targeting EGFR and mesothelin failed to significantly reduce tumor growth, HER2-targeted T-BsAbs displayed potent anti-tumor activity, eliminating tumors derived from two different cell lines with durable responses (Espinosa-Cotton et al., 2023). Here, EGFR is linked to neoplasm.